<DOC>
	<DOCNO>NCT02061865</DOCNO>
	<brief_summary>The primary objective study investigate safety intravitreal ( IVT ) REGN2176-3 patient neovascular wet age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Phase 1 Safety Study With Intravitreal ( IVT ) REGN2176-3 Patients Aged 50 Years Older With Wet AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Key Criteria : Men woman great equal 50 year age provide inform consent active subfoveal choroidal neovascularization ( CNV ) secondary wet AMD . 1 . Any prior treatment inhibitor PDGF ( plateletderived growth factor ) PDGFR ( plateletderived growth factor receptor ) 2 . Active neovascular AMD fellow eye require treatment 3 . Scar , fibrosis , atrophy study eye involve center fovea 4 . Presence retinal pigment epithelial tear rip involve macula study eye 5 . Prior vitrectomy study eye 6 . Any history macular hole stage 2 study eye 7 . Any intraocular periocular surgery within 3 month day 1 study eye , except lid surgery 8 . History corneal transplant study eye 9 . Positive serum human chorionic gonadotropin ( hCG ) / urine pregnancy test screen baseline visit The information list intend contain consideration relevant patient 's potential participation clinical trial inclusion/ exclusion criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>